Overview
PTGX market data
Price History
PTGX price chart · 1M
- O
- 136.01
- H
- 136.01
- L
- 126.61
- C
- 128.94
- Vol
- 37,233.00
Daily history from Aug 11, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $136.01
- Previous Close
- $136.47
- Day High
- $136.01
- Day Low
- $126.61
- 52 Week High
- $159.99
- 52 Week Low
- $73.23
- 7 Day Return
- -10.36%
- 30 Day Return
- -9.72%
- 90 Day Return
- -3.62%
- 1 Year Return
- +70.12%
- Daily Notional Volume
- $4.8M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 107.21 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 29.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $73.08 – $160.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.9B · P/B 8.88 · P/S 31.52.
Company News
10 captured
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184Benzinga ·
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190Benzinga ·
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsightGlobenewswire Inc ·